First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca


Milestone payment further bolsters Innate’s cash position

View post:
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca

Related Posts